ECVT $10.12 +1.61%

ECVT · Ecovyst Inc.

Track ECVT — free

$10.12 +0.16 (+1.61%) At close · Oct 2

Russell 2000 member Rebalance outlook locked

Market Cap

$1.11B

109.47M

Volume · Oct 2 1.08M Avg daily vol (3M) 1.3M

All webcasts

Earnings call · FY2026 Q2

Ecovyst Inc. (ECVT) Q2 2026 Earnings Call

Concluded Aug 5, 2026

Aug 5, 2026 0 turns

Period: FY2026 Q2
Runtime: —
Sources: 3 artifacts

Slides 14 8-K 10-Q

Executive readout · one minute

What matters this quarter

Ecovyst reported Q2 2026 sales of $250 million (+42% YoY) and adjusted EBITDA of $53.1 million (+27% YoY), completed the Calabrian acquisition on June 30, and raised full-year 2026 adjusted EBITDA guidance to $195–$207 million from $180–$195 million, including expected Calabrian contributions.

Calabrian acquisition 33 Regenerated sulfuric acid 13 Virgin sulfuric acid 13 Capital allocation and leverage 12 Sulfur pricing risk 11 Bolt-on M&A playbook 8

Management tone

Confident

Net tone +65 · low hedging

Grounding quotes

“Adjusted EBITDA of $53 million, solidly within our guidance range and up 27% compared to the second quarter of 2025.”
“we did tighten the guidance range now for the second consecutive quarter, which, you know, obviously implies an upward move on the midpoint.”
“we remain cautious about the potential for weaker demand in some industrial applications.”
“We don't believe that the price really has much room to go up from here, but we could see some moderate decreases in the future, but we're not expecting a large handle down or anything like that.”

Forward guidance

5 guided metrics

Management's latest ranges and targets are included below.

Research coverage

3 live sources

Open each available source without leaving this research workspace.

Revenue $249.96M +42% YoY

Diluted EPS $0.07 +40% YoY

Gross margin 19.9% -2.9 pp YoY

Net income $7.87M +31.4% YoY

Research materials

Open the source you need; every reader stays inside this workspace.

Presentation 14 pages 8-K earnings release Filed Aug 5, 2026 10-Q report Filed Aug 6, 2026 Company webcastOpen the original investor-relations page

Key takeaways

What improved, and what deserves a closer read.

↑ Constructive signals

Raised full-year 2026 adjusted EBITDA guidance to $195–$207 million (from $180–$195 million) on stronger legacy results and Calabrian contribution.
Raised full-year 2026 adjusted free cash flow guidance to $45–$55 million (from $40–$55 million) and adjusted EPS to $0.58–$0.72 (from $0.50–$0.65).
H1 2026 adjusted free cash flow of $12.8 million swung positive from $(2.4) million a year ago.

↓ Risks & pressure points

Net debt leverage ratio rose to 2.0x from 1.2x at year-end 2025 due to $100 million acquisition debt with no trailing Calabrian EBITDA.
Cautious near-term outlook for virgin sulfuric acid volumes into industrial applications and risk of destocking if sulfur prices ease.
Capital expenditures guidance raised to $85–$95 million from $80–$90 million, reflecting Gulf Coast expansion and Calabrian.

Forward guidance

From the 8-K filed Aug 5, 2026.

Metric	Period	Guided	Basis
Sales Initiated full-year 2026	full-year 2026	$1.02B – $1.06B	—
Capital expenditures Initiated full-year 2026	full-year 2026	$85M – $95M	—
Interest expense Initiated full-year 2026	full-year 2026	$18M – $22M	—
Depreciation & Amortization Initiated full-year 2026	full-year 2026	$80M – $84M	—
Adjusted Net Income Initiated full-year 2026	full-year 2026	$65M – $85M	Non-GAAP

Quarter detail

How the reported period landed and where the business moved.

Revenue · products & services

Virgin Sulfuric Acid$137.53M +85% YoY

Regenerated Sulfuric Acid and Treatment Services$103.08M +11.1% YoY

Catalyst Activation and Sulfur Dioxide Derivatives$9.35M +4.6% YoY

Read transcripts like this one from Claude, ChatGPT or your own code with the earnings call transcript API →